… the pathophysiology of diabetic macular edema has … with refractory diabetic macular edema
after three initial anti-VEGF … eyes with diabetic macular edema represents an important goal. …

… of the main complications of diabetes, the pathogenesis of DME is … pathogenesis.
Consequently, the intravitreal injections of anti-VEGF agents or corticosteroids are the …

… diabetic patients, with its pathogenesis still not completely elucidated. Vascular endothelial
growth factor (VEGF… of the current anti-VEGF drugs that only target VEGF-A. Intravitreal OPT-…

… production of VEGF or macular edema or both (Figure 1). … to target proteins with high affinity
and in a highly specific way. A … The antiviral and anti-angiogenic drug squalamine inhibits …

… key players (VEGF and molecules beyond VEGF) involved in … target pathways independent
from VEGF involved in the … containing 190 μg of drug and releasing 0.2 μg of drug per day, …

… Anti-VEGF intravitreal therapies target the hypoxia-induced expression of … (cGMP) modulator
drug therapy, which capitalizes on the various roles of NO signaling in DR pathogenesis. …

… molecules play an important role in DME pathogenesis and may be potential therapeutic
targets. … Given the importance of VEGF in DME pathogenesis, we could expect that patients with …

… after anti-VEGF treatment and the presence of anti-VEGF non-… In this review, we explore
the pathophysiology of DME and … Faricimab is an antibody that targets the Ang2 and VEGF-A …

… The pathogenesis of diabetic macular edema (DME) is complex. … activation may become an
attractive therapeutic target in the future. … VEGF and other inflammatory mediators in diabetic …

… pathogenesis of DME, we define patterns of response to treatment, and we report novel
treatment agents for persistent DME that target … The rationale for switching between anti-VEGF …